Multicenter, Single-Arm, Prospective Phase II Study of Neoadjuvant Cryo-Thermal Ablation Combined With Toripalimab and Chemotherapy for Resectable Stage IB-IIIB Non-Small Cell Lung Cancer

Neoadjuvant chemoimmunotherapy has improved outcomes in patients with resectable non-small cell lung cancer (NSCLC), but a substantial proportion of patients do not achieve a major pathological response. Cryo-Thermal Ablation may induce immunogenic tumor cell death and remodel the tumor immune microenvironment, potentially enhancing the antitumor activity of subsequent chemoimmunotherapy. This multicenter, single-arm, open-label, prospective Phase II study will evaluate the efficacy and safety of CT-guided Cryo-Thermal Ablation followed by toripalimab plus platinum-based doublet chemotherapy

Trial Details

NCT ID
NCT07855965
Phase
PHASE2
Sponsor
West China Hospital
Status
RECRUITING
Cancer Type
Lung Cancer
Interventions
  • Cryo-Thermal Ablation
  • Toripalimab
  • Platinum-based doublet chemotherapy
Locations (sample)
  • Chengdu, Sichuan, China|30.66667,104.06667
  • Chengdu, Sichuan, China|30.66667,104.06667
  • Chengdu, Sichuan, China|30.66667,104.06667
  • Chengdu, Sichuan, China|30.66667,104.06667
  • Luzhou, Sichuan, China|28.8903,105.42575

Key Eligibility Criteria

  • Diagnosis, Stage, and Resectability
  • Histologically or cytologically confirmed non-small cell lung cancer (NSCLC).
  • Clinical stage IB-IIIB according to the 9th edition IASLC/AJCC TNM classification.
  • For stage IB disease, only patients with a maximum tumor diameter of 4.0 cm (cT2aN0M0) are eligible.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lung Cancer Trials on Trialify →